First AI-developed vaccine could revolutionize prevention

Scientists may have finally found a way to stop playing cat-and-mouse with mutating viruses.

Researchers at the University of Cambridge have tested the first human vaccine built using AI, taking a step toward what many scientists have chased for years: a vaccine that protects against an entire family of viruses instead of playing perpetual catch-up.

Let’s break it down: Traditional vaccines target a specific virus, a process that’s effective up until that virus mutates and the vaccine becomes ineffective (the reason we need a new flu shot every year).

But instead of targeting one specific strain, researchers used AI to analyze thousands of genomes and identify genetic features that stay largely unchanged across a virus’ entire family tree, mutations included.

• Those shared features became the target of a single "super-antigen" vaccine designed to protect against all variants of a certain virus.
• In their initial trial, researchers created a vaccine to target all coronaviruses, including SARS, Covid, and related bat viruses that could someday make the jump to humans.

Moving the needle on prevention

Researchers believe the same AI-driven approach could eventually be used to create broad-spectrum vaccines for rapidly evolving viruses like influenza and Ebola. This approach aims to help stop future outbreaks before they become significant, and could also reduce the need to take new vaccines as viruses evolve.

• The first human trial involved 39 healthy volunteers, with results showing the vaccine was safe, well tolerated, and capable of generating antibodies against multiple coronavirus strains.
• Because it's DNA-based, the vaccine is generally more stable than mRNA versions, making it easier to transport and store.

Looking ahead...Experts say the mass production of universal vaccines for certain viruses is still years away, with larger trials needed to determine how much protection the new process provides, and how long it lasts.

In addition to coronaviruses, the research team is developing separate vaccines that could tackle the flu and Ebola.